BiOasis Presents Research Results On Transcend(TM) At International Symposium On The Blood-Brain Barrier

VANCOUVER, British Columbia, Sept. 7, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce that preclinical data on its proprietary Transcend™ (p97) technology for delivery of drugs into the brain was presented during the 13th International Symposium of the Blood-Brain Barrier, held in Zurich, Switzerland from Sept. 2 - 4, 2010.

biOasis' presentation entitled "A new carrier (p97) for delivery of therapeutic compounds beyond the BBB" was given by Dr. Reinhard Gabathuler on Friday, September 3, 2010 in Symposium 6: Vesicular Transport.

ABOUT TRANSCEND™ (p97)

biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood brain barrier - Transcend™. Current initiatives within the Transcend™ program include GMP production, preclinical studies and conjugation to a range of small molecule and biologic therapeutics. To address the unmet clinical need to transport drugs across the blood brain barrier biOasis intends to license Transcend™ to multiple corporate partners.

ABOUT INTERNATIONAL SYMPOSIUM OF THE BLOOD-BRAIN BARRIER:

The blood-brain and blood-cerebrospinal fluid barriers (BBB) tightly regulate the exchange of molecules and cells between the circulation and the central nervous system (CNS) and its functional integrity is crucial for neuronal homeostasis: a wide variety of neurological diseases are associated with a deregulated or defective BBB. The aim of this International Meeting is to gather scientists from academia and industry to discuss the latest developments in BBB research and forge new collaborations. Previous meetings have been held with great success in Potsdam (Germany), Cambridge (UK), Muenster (Germany), Szeged (Hungary), Salzburg (Austria), Amsterdam (Netherlands) and London (UK).

The program for the 13 ^th International Symposium encompasses all areas of BBB research and reflects the latest developments in BBB homeostasis, the neurovascular unit, microvascular permeability, intercellular junctions, choroid plexus, pericytes, extracellular matrix, pharmacological targeting of the brain, cell passage across the BBB and also the very latest on in vivo and in vitro BBB models. For more details on this symposium please visit www.physiol.uzh.ch/BBBSymposium .

ABOUT BIOASIS:

biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest™, a blood test for the diagnosis of Alzheimer's disease. BiOasis is also developing Transcend™, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncology and infectious disease applications.